NEURACEQ Drug Patent Profile
✉ Email this page to a colleague
When do Neuraceq patents expire, and what generic alternatives are available?
Neuraceq is a drug marketed by Life Molecular and is included in one NDA. There is one patent protecting this drug.
This drug has thirty-five patent family members in twenty-seven countries.
The generic ingredient in NEURACEQ is florbetaben f-18. One supplier is listed for this compound. Additional details are available on the florbetaben f-18 profile page.
DrugPatentWatch® Generic Entry Outlook for Neuraceq
Neuraceq was eligible for patent challenges on March 21, 2018.
By analyzing the patents and regulatory protections it appears that the earliest date
for generic entry will be March 18, 2029. This may change due to patent challenges or generic licensing.
Indicators of Generic Entry
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for NEURACEQ?
- What are the global sales for NEURACEQ?
- What is Average Wholesale Price for NEURACEQ?
Summary for NEURACEQ
| International Patents: | 35 |
| US Patents: | 1 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 5 |
| Clinical Trials: | 6 |
| Patent Applications: | 88 |
| What excipients (inactive ingredients) are in NEURACEQ? | NEURACEQ excipients list |
| DailyMed Link: | NEURACEQ at DailyMed |
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for NEURACEQ
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Recent Clinical Trials for NEURACEQ
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Life Molecular Imaging GmbH | Phase 3 |
| William Charles Kreisl | Phase 1/Phase 2 |
| Ulsan University Hospital | N/A |
Pharmacology for NEURACEQ
| Drug Class | Radioactive Diagnostic Agent |
| Mechanism of Action | Positron Emitting Activity |
US Patents and Regulatory Information for NEURACEQ
NEURACEQ is protected by one US patents.
Based on analysis by DrugPatentWatch, the earliest date for a generic version of NEURACEQ is ⤷ Sign Up.
This potential generic entry date is based on patent ⤷ Sign Up.
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
Patents protecting NEURACEQ
Stilbene derivatives and their use for binding and imaging amyloid plaques
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: NEURACEQ IS A RADIOACTIVE DIAGNOSTIC AGENT FOR POSITRON EMISSION TOMOGRAPHY (PET) IMAGING OF THE BRAIN TO ESTIMATE P-AMYLOID NEURITIC PLAQUE DENSITY IN ADULT PATIENTS WITH COGNITIVE IMPAIRMENT
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Life Molecular | NEURACEQ | florbetaben f-18 | SOLUTION;INTRAVENOUS | 204677-001 | Mar 19, 2014 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | Y | ⤷ Sign Up | ||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for NEURACEQ
When does loss-of-exclusivity occur for NEURACEQ?
Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:
Australia
Patent: 05316421
Patent: Stilbene derivatives and their use for binding and imaging amyloid plaques
Estimated Expiration: ⤷ Sign Up
Brazil
Patent: 0516408
Patent: derivados de estilbeno e seu uso para ligação e formação de imagem de placas de amilóide
Estimated Expiration: ⤷ Sign Up
Canada
Patent: 91534
Patent: DERIVES DE STILBENE ET LEUR UTILISATION POUR LA LIAISON ET L'IMAGERIE DE PLAQUES AMYLOIDES (STILBENE DERIVATIVES AND THEIR USE FOR BINDING AND IMAGING AMYLOID PLAQUES)
Estimated Expiration: ⤷ Sign Up
China
Patent: 1123995
Patent: Stilbene derivatives and their use for binding and imaging amyloid plaques
Estimated Expiration: ⤷ Sign Up
Costa Rica
Patent: 06
Patent: DERIVADOS DE ESTILBENO Y SU USO PARA ESTUDIOS DE UNION Y POR IMAGENES DE PLACAS AMILOIDES
Estimated Expiration: ⤷ Sign Up
Denmark
Patent: 13652
Estimated Expiration: ⤷ Sign Up
Eurasian Patent Organization
Patent: 2334
Patent: ПРОИЗВОДНЫЕ СТИЛЬБЕНА И ИХ ПРИМЕНЕНИЕ ДЛЯ СВЯЗЫВАНИЯ И ВИЗУАЛИЗАЦИИ АМИЛОИДНЫХ БЛЯШЕК (STILBENE DERIVATIVES AND THEIR USE FOR BINDING AND IMAGING AMYLOID PLAQUES)
Estimated Expiration: ⤷ Sign Up
Patent: 0701299
Patent: ПРОИЗВОДНЫЕ СТИЛЬБЕНА И ИХ ПРИМЕНЕНИЕ ДЛЯ СВЯЗЫВАНИЯ И ВИЗУАЛИЗАЦИИ АМИЛОИДНЫХ БЛЯШЕК
Estimated Expiration: ⤷ Sign Up
European Patent Office
Patent: 38298
Patent: Dérivés du stilbène et leur utilisation pour l'imagerie des plaques amyloïdes et pour se lier à elles (STILBENE DERIVATIVES AND THEIR USE FOR BINDING AND IMAGING AMYLOID PLAQUES)
Estimated Expiration: ⤷ Sign Up
Patent: 41465
Patent: DERIVES DE STILBENE ET LEUR UTILISATION POUR LA LIAISON ET L'IMAGERIE DE PLAQUES AMYLOIDES (STILBENE DERIVATIVES AND THEIR USE FOR BINDING AND IMAGING AMYLOID PLAQUES)
Estimated Expiration: ⤷ Sign Up
Patent: 13652
Patent: Dérivés de stilbène et leur utilisation pour l'imagerie des plaques amyloïdes et leur liaison (Stilbene derivatives and their use for binding and imaging amyloid plaques)
Estimated Expiration: ⤷ Sign Up
France
Patent: C0012
Estimated Expiration: ⤷ Sign Up
Hungary
Patent: 500014
Estimated Expiration: ⤷ Sign Up
Israel
Patent: 3946
Patent: STILBENE DERIVATIVES AND THEIR USE FOR BINDING AND IMAGING AMYLOID PLAQUES
Estimated Expiration: ⤷ Sign Up
Patent: 6091
Patent: תולדות סטילבן והשימוש בהם לקשור ולשיקוף רבדי אמילואיד (Stilbene derivatives and their use for binding and imaging amyloid plaques)
Estimated Expiration: ⤷ Sign Up
Japan
Patent: 28956
Estimated Expiration: ⤷ Sign Up
Patent: 08524243
Estimated Expiration: ⤷ Sign Up
Lithuania
Patent: 213652
Estimated Expiration: ⤷ Sign Up
Luxembourg
Patent: 647
Estimated Expiration: ⤷ Sign Up
Mexico
Patent: 07007380
Patent: DERIVADOS DE ESTILBENO Y SU USO PARA ESTUDIOS DE UNION Y POR IMAGENES DE PLACAS AMILOIDES. (STILBENE DERIVATIVES AND THEIR USE FOR BINDING AND IMAGING AMYLOID PLAQUES.)
Estimated Expiration: ⤷ Sign Up
Netherlands
Patent: 0719
Estimated Expiration: ⤷ Sign Up
New Zealand
Patent: 5942
Patent: Radiolabelled tilbene derivatives and their use for binding and imaging amyloid plaques
Estimated Expiration: ⤷ Sign Up
Norway
Patent: 9195
Estimated Expiration: ⤷ Sign Up
Patent: 073650
Estimated Expiration: ⤷ Sign Up
Poland
Patent: 13652
Estimated Expiration: ⤷ Sign Up
Portugal
Patent: 13652
Estimated Expiration: ⤷ Sign Up
Singapore
Patent: 4363
Patent: STILBENE DERIVATIVES AND THEIR USE FOR BINDING AND IMAGING AMYLOID PLAQUES
Estimated Expiration: ⤷ Sign Up
Slovenia
Patent: 13652
Estimated Expiration: ⤷ Sign Up
South Africa
Patent: 0705104
Patent: Stilbene derivatives and their use for binding and imaging amyloid plaques
Estimated Expiration: ⤷ Sign Up
South Korea
Patent: 1321619
Estimated Expiration: ⤷ Sign Up
Patent: 070093427
Patent: STILBENE DERIVATIVES AND THEIR USE FOR BINDING AND IMAGING AMYLOID PLAQUES
Estimated Expiration: ⤷ Sign Up
Spain
Patent: 26655
Estimated Expiration: ⤷ Sign Up
Ukraine
Patent: 996
Patent: ПРОИЗВОДНЫЕ СТИЛЬБЕНА И ИХ ПРИМЕНЕНИЕ ДЛЯ СВЯЗЫВАНИЯ И ВИЗУАЛИЗАЦИИ АМИЛОИДНЫХ БЛЯШЕК;ПОХІДНІ СТИЛЬБЕНУ ТА ЇХ ЗАСТОСУВАННЯ ДЛЯ ЗВ'ЯЗУВАННЯ ТА ВІЗУАЛІЗАЦІЇ АМІЛОЇДНИХ БЛЯШОК (STILBENE DERIVATIVES AND THEIR USE FOR BINDING AND IMAGING AMYLOID PLAQUES)
Estimated Expiration: ⤷ Sign Up
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
See the table below for additional patents covering NEURACEQ around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Japan | 4950031 | ⤷ Sign Up | |
| Netherlands | 300719 | ⤷ Sign Up | |
| Mexico | 2007007380 | DERIVADOS DE ESTILBENO Y SU USO PARA ESTUDIOS DE UNION Y POR IMAGENES DE PLACAS AMILOIDES. (STILBENE DERIVATIVES AND THEIR USE FOR BINDING AND IMAGING AMYLOID PLAQUES.) | ⤷ Sign Up |
| China | 101151886 | Image display and image displaying method | ⤷ Sign Up |
| Denmark | 2213652 | ⤷ Sign Up | |
| European Patent Office | 2213652 | Dérivés de stilbène et leur utilisation pour l'imagerie des plaques amyloïdes et leur liaison (Stilbene derivatives and their use for binding and imaging amyloid plaques) | ⤷ Sign Up |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for NEURACEQ
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 2213652 | CA 2015 00018 | Denmark | ⤷ Sign Up | PRODUCT NAME: FLORBETABEN (18F); REG. NO/DATE: EU/1/13/906/001 20140220 |
| 2213652 | 8/2015 | Austria | ⤷ Sign Up | PRODUCT NAME: FLORBETABEN (18 F); REGISTRATION NO/DATE: EU/1/13/906/001 (MITTEILUNG) 20140224 |
| 2213652 | SPC/GB15/010 | United Kingdom | ⤷ Sign Up | PRODUCT NAME: FLORBETABEN (18F), WHICH IS (4-((E)-2-(4-(2-(2-(2-(1F)FLUOROETHOXY)ETHOXY)ETHOXY)PHENYL)ETHENYL)-N-METHYLANILINE); REGISTERED: UK EU/1/13/906/001 20140224 |
| 2213652 | 1590005-3 | Sweden | ⤷ Sign Up | PRODUCT NAME: FLORBETABEN (18F); REG. NO/DATE: EU/1/13/906 20140224 |
| 2213652 | 92647 | Luxembourg | ⤷ Sign Up | PRODUCT NAME: FLORBETABEN (18F). FIRST REGISTRATION: 20140224 |
| 2213652 | 15C0012 | France | ⤷ Sign Up | PRODUCT NAME: FLORBETABEN (18F); REGISTRATION NO/DATE: EU/1/13/906/001 20140224 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - Digital Marketing for Life Sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
